Sign-up for our newsletter
Pilot & Feasibility
External Funding Programs
Protocols & Methods
Reagents & Resources
Tissues & Samples
IMPC / KOMP Data
Pilot & Feasibility
External Funding Programs
Medical University of South Carolina
Cognitive Impairment in Diabetes: Endothelial Mechanisms & Intervention
Diabetes doubles the risk vascular cognitive impairment and dementia (VCID), a disease spectrum ranging from mild cognitive impairment to dementia and is associated with small vessel disease (SVD) of the brain, especially deep in the white matter that further complicates the disease by causing infarctions due to the occlusion of terminal arterioles. Yet, early mechanisms contributing to amplified SVD and cognitive decline remain unknown. Given that diabetes mediates early cerebrovascular dysfunction, and microemboli are quite common in the cerebral circulation and can penetrate into the brain parenchymal arterioles without causing an infarction, with the support of a 2017 DiaComp award, we started testing the hypothesis that entrapment of microemboli in dysfunctional vessel walls leads to the development of SVD ultimately resulting in VCID in diabetes. Phase III Lacunar Intervention Trial (LACI-2) that was announced in early 2018 to assess the safety and efficacy of isosorbide mononitrate (ISMN) and cilostazol, two commonly prescribed drugs to improve vascular function, in the prevention of lacunar strokes and progression of SVD provided a translational direction for our exciting preliminary data. Therefore, the objective of this pilot application is to refine the microemboli model of VCID and begin preclinical testing with ISMN and cilostazol for the prevention/treatment of SVD and VCID in diabetes. The working hypothesis is that early endothelial dysfunction in diabetes facilitates entrapment of microemboli leading to SVD and VCID. In 2 aims, by using histopathological assessment and longitudinal MRI imaging & behavioral testing, we will determine 1) the impact of microemboli on temporal development of SVD and VCID in diabetes, and 2) the effectiveness of ISMN and cilostazol combination in the prevention of SVD and cognitive decline in diabetes. The data of this study will provide essential evidence that endothelial dysfunction plays a critical role in the pathogenesis of SVD in diabetes. We also will establish a clinically relevant model to develop further studies on neurovascular protection in the high risk groups. Finally, we will provide crucial preclinical data specific for diabetes with therapeutics that are on clinical trials for the prevention of SVD in general population. Given that cognitive impairment is a wide spectrum that can start early in life and diabetes is the most rapidly increasing risk factor for cognitive decline, we believe that this translational study will provide critical data to fully develop this project to advance the field and make a significant positive impact on public health.
Increased small vessel disease in the brain and cognitive impairment in diabetes
Diabetes is an increasing risk factor for vascular cognitive impairment (VCI), which is defined as cognitive deficits associated with small vessel disease (SVD) and/or lacunar infarction due to the occlusion of terminal arterioles by emboli in the brain. Microemboli even in sizes that would not cause complete occlusion are quite common in the cerebral circulation and are more so in patients with diabetes that present with a hypercoagulable state. Lack of understanding of the role and mechanisms by which microemboli can contribute to increased disease burden in diabetes is a critical gap in our knowledge. The objectives of this DiaComp Pilot & Feasibility Program grant application are to begin addressing this important clinical problem by establishing a novel animal model and gathering proof-of-concept data to implicate the vascular dysfunction and microemboli interaction in the development of cerebral SVD preceding the VCI in diabetes. We propose that the microemboli injected through the internal carotid artery will accelerate the development of cerebral SVD in diabetes ultimately resulting in VCI without increasing microinfarcts in a sex independent manner. We will examine the cerebral neuronal and vascular changes by neuropathology assay in both male and female animals. We will also examine the neurological and cognitive behavioral tests, and brain imaging to assess the cognitive function. The results of this translational study first will provide the proof-of-concept pilot data that microemboli are pathological even in the absence of increased microinfarction in diabetes. Second, we will establish a new clinically relevant model to study the mechanisms of VCI, which will enable us to develop the studies on neurovascular protection strategies especially in the high-risk groups. Third, we will provide novel data regarding the impact of sex on the development of VCI in diabetes.
Drag a column header and drop it here to group by that column
Increased small vessel disease in the brain and cognitive impairment in diabetes (Li, Weiguo)
View Progress Report Document
No uploaded documents found.
Year: 2018; Items: 1
Post-stroke neovascularization and functional outcomes differ in diabetes depending on severity of injury and sex: Potential link to hemorrhagic transformation.
Li W, Valenzuela JP, Ward R, Abdelbary M, Dong G, Fagan SC, Ergul A
, 2018 (311), 106 - 114
No uploaded documents found.
No protocols found.
The DiaComp Steering Committee is the governing body of the consortium. The principle function of this committee is to guide the scientific direction of the consortium. This is accomplished by creating various subcommittees necessary to advance the scientific goals and providing guidance to the broader complications research community. Policies for the consortium are developed through consultation with the
External Evaluation Committee
The DiaComp Cardiovascular Committee has the principal function of furthering the mission of the consortium with regard to diabetic cardiomyopathy and macrovascular disease.
Curation Flag Information
New comment to be added:
No experiments found.
No strains found.
No models found.
Welcome to the DiaComp Login / Account Request Page.
Note: Passwords are case-sensitive.
Please save my Email Address on this machine.
Not a member?
If you are a funded DiaComp investigator, a member of an investigator's lab,
or an external advisor to the consortium, please
request an account.
Forgot your password?
Enter your Email Address and
There was a problem with the page:
Safari Browser Detected...
We strive to make the DiaComp site compatable with as many browsers as possible, but some of our third party tools don't work with the Safari browser.
In order to explore this site we highly recommend using the most recent versions of the following browsers:
© 2018 DiaComp.org
All rights reserved
Please acknowledge all posters, manuscripts or scientific materials that were generated in part or whole using funds from the Diabetic Complications Consortium(DiaComp) using the following text:
Financial support for this work provided by the NIDDK Diabetic Complications Consortium (RRID:SCR_001415, www.diacomp.org), grants DK076169 and DK115255
Citation text and image have been copied to your clipboard. You may now paste them into your document. Thank you!